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ABSTRACT
Lyme arthritis, the most common manifestation of late Lyme disease, has been associated with the
presence of Borellia burgdorferi in the joint. However, it is still unclear whether the pathogen itself is able
to elicit such a sustained inflammatory response, or whether an aberrant immunological reaction of the
host is the main driving force. Borrelia antigens, including lipoproteins, flagellin and DNA, are ligands of
Toll-like receptors, and can thus elicit a strong stimulation of host cells, such as neutrophils,
mononuclear cells and resident tissue cells. Understanding the molecular basis of the signalling events
caused by Borrelia lipoproteins will lead to a greater understanding of inflammation in Lyme arthritis
and, hopefully, new treatment strategies for chronic antibiotic-resistant disease.
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INTRODUCTION
The term ‘Toll’ was first used to describe a cell-
surface receptor governing dorsoventral axis
polarity in early Drosophila melanogaster (fruit fly)
larvae [1]. In addition to developmental roles, it
became clear that Toll receptors play an essential
role, together with other antimicrobial peptides,
in the activation of non-specific antifungal
defence mechanisms in the fly [2]. A comparable
system of antimicrobial defence mechanisms
has been identified in humans by studying lipo-
polysaccharide (LPS)–host interactions. These
receptors have been termed ‘Toll-like receptors’
(TLRs). It is now known that TLRs play an
important role in the signalling of many patho-
gen-derived molecules, and also in some endog-
enous proteins associated with activation of the
immune system. To date, ten human and nine
murine trans-membrane proteins have been
reported to belong to the mammalian TLR family
[3,4]. All TLRs are characterised by an extracellu-
lar domain (ectodomain) with leucine-rich repeats
(LRR), and a single trans-membrane domain
followed by an intra-cytoplasmic domain that is
required for signal transduction. The intra-cyto-
plasmic domain is also called the TIR domain
(TOLL ⁄ interleukin-1 receptor homology domain)
on the basis of its homology with the interleukin-1
type-I receptor (IL-1RI) [5]. It has been demon-
strated in various studies that Borrelia-derived
antigens can interact with the TLR system and
thereby stimulate the production of pro-inflam-
matory factors.
Borrelia burgdorferi, the spirochaete that causes
Lyme disease, can invade and persist in multiple
organs for long periods. Lyme disease is a
multisystemic disorder, which involves primarily
the joints, the heart, the central and peripheral
nervous system, and the skin. The initial stages of
Lyme disease are treated with antibiotics. How-
ever, if misdiagnosed or left untreated, the spiro-
chaete may spread from a localised skin infection
to other body parts and tissues. Treatment- or
antibiotic-resistant Lyme borreliosis has been
described in the later stages of the disease. In
human and murine disease, the pathology of
Lyme borreliosis is considered to be related to the
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presence of the bacterial pathogen in tissues,
suggesting that either living or dead bacteria,
or bacterial products, might be responsible for
eliciting inflammation.
B. burgdorferi has been shown to produce a
number of membrane-associated lipoproteins,
and many of these are expressed preferentially
during mammalian infection. Several of these
lipoproteins have been shown to directly stimu-
late immunological effector cells responsible for
mediating an innate immune response; such
responses include induction of inflammatory
mediators by macrophages [6], the expression of
adhesion molecules and the production of super-
oxide by neutrophils [7], induction of NF-kB
nuclear translocation and up-regulation of down-
stream inflammatory events in endothelial cells
[8], activation of mast cells [9], and mitogenesis
and immunoglobulin production in B-cells [6,10].
The inflammatory events induced by these lipo-
proteins suggest that persistence of B. burgdorferi
in tissues could contribute to the tissue pathology
of Lyme disease [11–13].
The role of TLR2 in B. burgdorferi infection has
been studied extensively. This review describes
the role of the major TLRs in host defence and,
in particular, the role of TLR2 in relation to
B. burgdorferi-induced inflammation.
EXPRESSION OF PATTERN
RECOGNITION RECEPTORS AND
PATHOGEN RECOGNITION
The innate recognition of pathogens is mediated
initially by a set of germline-encoded receptors
known as pattern recognition receptors (PRRs).
These can directly recognise conserved molecular
structures on pathogens, which are known as
pathogen-associated molecular patterns (PAMPs).
PAMPs are shared by groups of microorganisms
[14]. There are only a few main features that
characterise PAMPs: they are usually expressed
by microbes, but not by host cells; they show little
variation among microorganisms of a given class;
their expression can be essential for the survival
and pathogenesis of the microbe; and limited
variation of the pathogen allows a class recogni-
tion of microbes, and prevents, in part, the
development of mutants which could escape
recognition by the host immune system [15].
It has been demonstrated that a range of
bacterial molecules, such as hypomethylated
DNA with CpG motifs, lipoteichoic acid, pepti-
doglycans, lipoarbinomannans, lipopeptides and
choline-containing phosphoglycolipids, can inter-
act with the mammalian innate immune system.
Receptors of PAMPs include secreted PRRs (LPS-
binding protein; LBP), cell surface PRRs (such as
TLRs, CD14, the macrophage scavanger receptor
and the mannose receptor), and intracellular
PRRs (dsRNA-activated protein kinase) [15]
(Table 1, Fig. 1 and Fig. 2).
The recent addition of TLRs to the list of cell-
surface PRRs has opened a new field of research.
TLR-family members are expressed by host cells
involved in the first line of host defence, including
neutrophils, macrophages, dendritic cells, mucos-
al epithelial cells [16] and synovial fibroblasts [17].
TLR2 and TLR4 are the major receptors for
bacterial lipoproteins and LPS, respectively. Both
receptors are also expressed on B- and T-cells,
which mediate the complex adaptive immunity
by a large repertoire of antigen-specific immuno-
globulin class receptors [18]. Thus, the innate and
adaptive branches of the host’s immune system
are well-connected. The innate system is thought
to keep infectious pathogens at bay until the more
specific adaptive response is mounted. With the
exception of TLRs 3, 7, 8 and 9, which are intra-
cellular receptors, TLRs are generally expressed
on the cell-surface. The subcellular localisation of
TLR4 differs in macrophages and intestinal epi-
thelial cells. In macrophages, TLR4 is expressed
on the cell-surface and is internalised following
engagement of a ligand, whereas in epithelial cells
it resides in the Golgi apparatus [16,19].
ROLE OF TLRs IN HOST IMMUNE
DEFENCE
One of the distinctive features of the immune
system is that it relies on cell migration for
surveillance, attack, containment and clearance
of invading pathogens. Two types of cell migra-
tion are used by the cells of the innate and
adaptive immune systems, i.e., inducible and
homeostatic cell migration. Inducible cell migra-
tion is generally triggered as the result of the
sensing of pathogens through PRRs, as in neutro-
phil recruitment to the local site of infection.
Steady-state or homeostatic cell migration allows
naı¨ve lymphocytes to circulate among the secon-
dary lymphoid tissues throughout the body.
Once an antigen is encountered via B- or T-cell-
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specific receptors, an adaptive immune reaction
might be mounted. This pathway is constitu-
tive and does not require induction through TLRs
[20].
Innate recognition of PAMPs through TLRs
initiates an inflammatory response characterised
by the recruitment of the cells to the site of
infection. Cell migration from peripheral blood
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Fig. 1. Toll-like receptors and their ligands
Table 1. Toll-like receptors and their ligands
Toll-like receptor Ligands Origin of ligand, pathogens or disease
TLR1 • only signals as dimer when combined with TLR2 for all its ligands
• recognises Borrelia burgdorferi OspA, required for adaptive immune response Lyme disease, B. burgdorferi
• lipopeptides
• modulin
TLR2 • associates with TLR1, TLR6
• lipoproteins/lipopeptides, B. burgdorferi OspA Lyme disease, B. burgdorferi
• peptidoglycan
• lipoteichoic acid
• lipoarbinomannan (mycobacterial),
phenol soluble modulin (Staphylococcus epidermidis),
glycoinositolphospholipids (Trypanosoma cruzi)
M. tuberculosis
Chagas disease
• glycolipids (Treponenma maltophilum)
• Porin (Neisseria)
• zymosan (yeast) fungal sepsis
• HSP70 (host)
TLR3 • double stranded RNA double stranded RNA viruses
TLR4 • Gram-negative enteric LPS (requires co-receptors MD-2, CD14) Gram-negative bacteria
• F protein Respiratory syncytial virus
• taxol plant
• Chlamydia HSP60 Chlamydia trachomatis and
• HSP60 and HSP70 Chlamydia pneumoniae
• polysaccharide fragments of heparan sulphate host
• fibrinogen host
TLR5 • flagellin from bacteria flagellated bacteria, Gram-negative bacteria
and Gram-positive bacteria
TLR6 • soluble tuberculosis factor
• small antiviral compounds
TLR7 • small antiviral compounds viral infections
TLR8 • small antiviral compounds viral infections
TLR9 • bacterial unmethylated DNA as CpG motif bacterial and viral infections
TLR10 • expressed on B-Cells and plasmacytoid dendritic cells, but specific
ligands are unknown
unknown
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to the inflamed tissues is a multistep process
[20]. Two types of signals mediate these steps,
i.e., diffusible chemotactic factors and cell-sur-
face adhesion molecules. Activation of cells by
TLRs induces the expression of selectin, chemo-
kine and chemokine receptor genes in local
tissue cells and migratory immune effector cells
that regulate cell migration to the sites of
inflammation [21] (Fig. 2). In addition, TLR
engagement initiates a signalling pathway that
stimulates the cellular components of the host
innate defence system and leads to an induction
of reactive oxygen species and nitrogen interme-
diates [5]. It can also stimulate the first steps of
the adaptive immune system by induction of
pro-inflammatory cytokines and the up-regula-
tion of co-stimulatory molecules in antigen-pre-
senting cells. When sensing inflammatory
signals, leukocytes rely first on vascular endot-
helial cells. This process is mediated by selectins
expressed by the endothelium, and by carbohy-
drate ligands on leukocytes. Selectins are dis-
played rapidly on the endothelial surface, either
after direct recognition of pathogens through
TLRs, or by tumour necrosis factor secreted from
activated tissue macrophages. Key inflammatory
chemokines produced during microbial infection
include interleukin-8 (IL-8 ⁄CXCL8), monocyte
chemo-attractant protein-1 (MCP-1 ⁄CXCL1),
MCP-2 (CCL8), macrophage inflammatory pro-
tein-1 a (MIP-1 a ⁄CCL3) and RANTES (CCL5)
[20,22]. Cell adhesion molecules are also induced
directly by TLRs, or indirectly through tumour
necrosis factor and IL-1, which are produced by
TLR-activated resident tissue macrophages [23].
Differential expression of chemokines [24], adhe-
sion molecules [12], matrix metalloproteinases
[25] and cyclo-oxygenases has been demonstra-
ted in synovial cells exposed to B. burgdorferi
isolates Geho and B31 [25]. It may be that
different B. burgdorferi isolates directly induce
or signal through TLRs by different mechanisms,
leading to a differential expression of molecules
relevant for inflammation. This could be a major
cause of the variation of inflammation in time
and severity associated with Lyme disease.
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Fig. 2. Toll-like receptor (TLR) signalling pathways. Binding of a pathogen-associated molecular pattern (PAMP) to a
particular TLR leads to the activation of TIR, and triggers a series of events leading to increased expression of pro-
inflammatory genes. TLRs and IL-1Rs share a common adaptor molecule MyD88. After binding of a ligand, MyD88 is
recruited to the TIR Toll ⁄ interleukin-1 receptor homologous region (TLR ⁄TIR) receptor complex, which is then joined by
IL-1R-associated protein kinase-1 (IRAK-1), IRAK-4 and tumour necrosis factor receptor associated factor 6 (TRAF6).
IRAK-1 and TRAF-6 then dissociate from this complex and associate with another complex of transforming growth factor
b-activated kinase (TAK-1) and TAK-1 binding proteins 1 and 2. TAK-1 is activated, which in turn activates the IjB kinase
(IKK) complex. IKK-mediated phosphorylation of IjB leads to its ubiquitination and degradation, thereby unmasking the
nuclear localisation domain of NF-jB [80]. After NF-jB translocation into the nucleus, NF-jB can activate multiple pro-
inflammatory genes including TNF-a, IL-1 and IL-6 [80]. See main text for further explanation of abbreviations.
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The action of the innate immune system in
peripheral tissues is thought to have a limited
ability to eradicate pathogens in mammals [26]. A
more effective host defence is achieved by the
activation of adaptive immune responses, which
mostly takes place in secondary lymphoid tissues
such as lymph nodes [26]. Immature dendritic cells
(DCs) play an essential role in the communication
between the peripheral site of infection and these
secondary lymphoid tissues [27]. In contrast to
macrophages, which function mainly to eradicate
pathogens, DCs are important for sensing the
invading pathogen and for transferring the infor-
mation to the adaptive immune system. In order to
activate T-cells, DCs need first to leave the periph-
eral tissues and to migrate to regional lymph nodes
[26]. In mice and humans, dendritic cell trafficking
is mediated by chemokine receptors following
stimulation of TLRs [28,29]. LPS, a typical PAMP
interacting with TLRs, can down-regulate the
expression of chemokine receptors, such as CCR5,
and up-regulate CCR7 expression on DCs. TLR
signalling stimulates the maturation of DCs. Thus,
bacterial infection activates DCs and can stimulate
them to produce mainly TH1-inducing cytokines
such as IL-12. Differentiation into TH1 or TH2 CD4
+ effector T-cells [30] can be directed by DCs,
depending upon the particular DC subsets, the DC
maturation stage, or the DC to T-cell ratio [26,31].
Stimulation of T-cells is mediated by the pres-
entation of MHC molecule-associated pathogen-
derived peptides, combined with a variety of
secondary signals delivered by co-stimulatory
molecules such as CD80 ⁄CD86 [5,26]. T-cell differ-
entiation is important for the establishment of an
effective adaptive immunity [30]. TH1 cells secrete
mainly the effector cytokine IFN-c and are involved
in cellular immunity. TH2 cells produce the effector
cytokines IL-4, IL-10 and IL-13, and are thought to
be involved in humoral immunity. Therefore, TLR-
stimulated DCs tend to direct T-cell differentiation
towards the TH1 cell type. These observations show
that TLRs are crucial, not only in the early phase of
infection, but also in linking innate and adaptive
immunity throughout the entire course of the host
defence response.
MAMMALIAN TLRs AND THEIR
LIGANDS
TLR1 and TLR2 are responsible for the response
to triacylated bacterial lipoproteins [32,33]. Virus
replication in infected cells results in the gen-
eration of dsRNA and induction of type-I
interferon; dsRNA acts as a PAMP because it
is not a constituent of host cells, and is
recognised by TLR3 (Fig. 1) [34]. Most patho-
genic and commensal bacteria produce flagellin.
Flagellin is a monomeric structural subunit of
bacterial flagella, and TLR5 is able to sense
flagellin. Flagellin shows a potent pro-inflam-
matory activity by inducing IkB degradation,
and thus NF-kB activation [35]. TLR6 and TLR2
recognise diacylated bacterial lipoproteins [36].
CpG oligonucleotides derived from bacterial
DNA signal through TLR9 [37].
There is broad ligand specificity for different
ligands recognised by different TLRs. How such
different ligands, either proteins or lipids, can
induce signals via the same TLR is still unclear.
A set of TLRs can cluster to induce responses to
a specific ligand [38]. It has been suggested that
the ability of TLR2 to bind several ligands is
based on its ability to form heterodimers with
other TLRs, particularly TLR6 or TLR1 [38].
Thus, TLR2 appears to broaden its repertoire of
specificities indirectly by forming at least two
distinct types of functional heterodimers with
other TLRs. This observation has been suppor-
ted by a study of knock-out mice. It has also
been demonstrated that TLR1 signalling is not
necessary, but that it can enhance the stimula-
tory response to triacylated lipoproteins via
TLR2. In contrast, TLR6 seems to be necessary
for a host response to diacylated lipoproteins
via TLR2 [36].
Proteins other than the TLRs themselves have
been shown to be necessary for TLR binding and
signalling. The small molecule MD-2 is required
for responses to LPS via TLR4 [39], and may also
form aggregates with TLR4 receptors [40]. The
role of CD14 in binding a variety of microbial
compounds, thereby enhancing activity for TLR
ligands towards cellular activation, has also been
established [41].
TLRs AND BORRELIA BURGDORFERI
The severity of clinical symptoms associated with
bacterial diseases may vary according to the type
and abundance of the infectious agent, the affec-
ted tissue, and co-existing illnesses. However,
similar host responses have also been observed.
For example, several clinical and immunological
Singh and Girschick Toll-like receptors in Borrelia inflammation 709
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 705–717
similarities can be seen during infection with
Treponema and Borrelia spp., and between Gram-
negative and Gram-positive sepsis [42]. Hence, it
can be speculated that the pathophysiological
similarities observed with diverse infections are
caused by activation of analogous signalling
pathways in response to bacterial exposure.
Sensing of different pathogen-derived mole-
cules via TLRs can mediate host inflammatory
reactions to a range of microbial pathogens.
Understanding the immunopathology of Lyme
borreliosis is still a major challenge. Although
B. burgdorferi can induce a strong bactericidal
immune activation, e.g., in phases of arthritis, the
causative agent of Lyme borreliosis seems to be
able to persist in humans, which probably contri-
butes to a chronic pathology in the immunocom-
petent host [11]. A remitting and episodic course
of inflammation has been described, indicating a
repetitive confrontation of the immune system
with spirochaetal components [43]. The genome
of B. burgdorferi contains c. 150 genes that encode
putative lipoproteins. B. burgdorferi does not
produce LPS [44], nor does its genome encode
the enzymes required for LPS synthesis [45], but it
manufactures abundant lipoproteins [46]. Thus
lipoproteins seem to provide the major inflam-
matory stimulus associated with infection. The
existence of a specific receptor for lipoproteins
could provide a mechanism by which bacteria
could activate inflammation directly. Bacterial
lipoproteins and LPS share many characteristics,
including a biologically active lipid modification,
the types of cells that are responsive, and the
types of responses that are elicited [47].
Spirochaetal lipoproteins and synthetic lipo-
hexapeptide analogues are potent activators of
monocytes ⁄macrophages, neutrophils, lympho-
cytes, endothelial cells and fibroblasts [42]. The
acyl modification of the peptides is essential for
their pro-inflammatory activities. Strong pro-
inflammatory capacities for the lipoproteins of B.
burgdorferi were described first for outer-surface
proteins A and B. Both are highly immunogenic
[48] and have been the basis for the development
of Lyme disease vaccines [49]. These compounds
exhibit a triacylated lipid anchor structure, com-
prising an N-palmitoyl-S-[2,3-bis(palmitoyloxy)-
(2RS)-propyl]-(R)-cysteinyl (Pam3Cys) moiety at
the N terminus [50], which is a feature that has
also been described for lipoproteins from Escheri-
chia coli [51]. A Pam3Cys moiety has also been
described in another spirochaete, Treponema palli-
dum [52], and has been reported to be present in
cytokine-inducing lipoproteins from Mycobacteri-
um and Mycoplasma spp. [53,54]. Thus, Pam3Cys
can be regarded as a conserved molecular motif
among different classes of bacteria. The inflam-
matory activities attributed to B. burgdorferi
lipoproteins include an ability to directly induce
NF-jB nuclear translocation, resulting in cytokine
production, adhesion molecule expression, and
generation of nitric oxide and superoxide [55–58].
Both TLR2 and TLR4 are expressed on the surface
of a wide variety of human cells [3,59], and have
been reported to have a role in the recognition of
bacterial lipoproteins and lipopolysaccharide,
respectively, as well as in the induction of NF-jB
and activator protein-1.
It has been demonstrated that defects in TLR1
and TLR2 can abrogate the response to OspA in
OspA-vaccinated mice. It has also been reported
that humans who are hypo-responsive to OspA
vaccination have altered cell-surface expression of
the TLR1 receptor, and may have a disturbance in
the TLR1-mediated signalling pathway. These
studies provide a link between TLR1, TLR2 and
acquired humoral immune responses [33].
Wang et al. [60] performed a study of the
impact of TLR2-mediated signalling on host
defence and susceptibility to infection by using
B. burgdorferi isolates RST1 and RST3A in TLR2-
deficient mice. Mice infected with RST1 devel-
oped more severe arthritis and carditis compared
with the mice infected with RST3, demonstrating
that different genotypes of B. burgdorferi differ in
their pathogenicity [61]. RST3A cells were more
likely to be killed by the counter-attack of the
host defence mechanism in the early stage of
infection. In TLR2-deficient mice infected with
RST1, the innate host defence system was shown
to be impaired, which resulted in a significant
increase in the number of spirochaetes in various
tissues. Quantitative differences in spirochaete
levels were thought to reflect the impairment of
host immunity. Spirochaete dissemination would
be limited under immunocompetent conditions,
resulting in the clearance of bacteria from target
tissues. However, despite significantly higher
numbers of spirochaetes, TLR2-deficient mice
developed a milder carditis than wild-type
C3H ⁄HeJ mice. This was considered to be
evidence that TLR2-mediated signalling is
involved in antibacterial action, and also in
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pathological pro-inflammatory responses and
disease evolution. During the course of infection,
bacteria may stimulate specific cell-signalling
receptors, resulting in a selective induction of
host genes that may even facilitate bacterial
invasion, colonisation and growth, supporting
the inflammatory reaction. The TLR2 receptor is
expressed on the surface of mammalian mono-
cytes or macrophages [62]. The absence of TLR2-
dependent signalling could result in disruption
of the host inflammatory response mediated by
macrophages. The latter might not be beneficial
in every case.
It is possible that only a limited number of
spirochaetes are required to initiate host inflam-
matory signalling in target tissues. Once the
density of spirochaetes in joints reaches a partic-
ular threshold, pro-inflammatory signalling could
be activated and may result in severe arthritis in
mice, regardless of the number of spirochaetes. In
the TLR2-deficient mouse, it is also possible that
spirochaetes were cleared by other host defence
mechanisms independent of the TLR2 pathway.
TLR2-independent pathways could be mediated
by non-lipoprotein components of spirochaetes,
such as flagellin, CpG motif-containing DNA and
glycolipids [4,60].
Several studies have demonstrated a critical
role for Borrelia-specific immunoglobulin (Ig) in
the protective host defence to B. burgdorferi [63–
65]. B. burgdorferi lipoproteins have been reported
to possess potent B-cell mitogenic properties that
are capable of stimulating polyclonal activation,
proliferation and Ig production in vitro. Increased
numbers of B. burgdorferi spirochaetes in TLR2-
deficient mice cannot be attributed to a defective
humoral immune response, as anti-spirochaete
IgG levels were normal. This suggests that effect-
ive elimination of B. burgdorferi requires not only
specific anti-Borrelia Ig, but also TLR2-expressing
effector cells. TLR2 is reported to be expressed in
activated B-lymphocytes within germinal centres,
but is not expressed by resting B-lymphocytes
[59,66]. These results suggest that B-cell activation
by lipoproteins may be subsequent to TLR2
engagement.
Neutrophils have been shown to play a critical
role in spirochaete clearance [67], and may
be very important in controlling numbers of
Ig-opsonised B. burgdorferi in TLR2-deficient mice.
It has been suggested that the lipoprotein–TLR2
interaction plays a crucial role in activating cells
of the innate defence system, leading to phago-
cytosis and killing of spirochaetes. In addition,
resident glial cells, including astrocytes and
microglia, seem to play an important role in the
host response to B. burgdorferi in neuroborreliosis.
Microglia are resident immune cells of the central
nervous system, and are descendents of the same
cellular lineage as monocytes and macrophages.
Rasley et al. [68] demonstrated that exposure of
microglial cells to B. burgdorferi leads to an
induction of TLR2 and CD14 genes.
One candidate for non-lipoprotein stimulatory
activity in sonicated B. burgdorferi is unmethylated
CpG DNA, which has been shown to activate
murine cells through TLR9 signalling [37]. Addi-
tionally, flagella from two diverse bacteria, Listeria
monocytogenes and Salmonella Typhimurium, have
been reported to signal via TLR5, suggesting that
Borrelia flagella are also able to stimulate via
TLR5.
Metalloproteinases (MMPs) have been implica-
ted in many inflammatory processes involving the
nervous system and the joints, both of which are
sites of injury in Lyme disease [25]. It has been
demonstrated that secretion of MMP-9 is induced
selectively by TLR2 in human and murine mono-
cytic cells stimulated with B. burgdorferi [69].
Analysis of nuclear extracts indicated that activa-
tor protein (AP-1) plays a role in transcriptional
activation of MMP-9 through TLR2 in monocytes.
Secretion of MMP-1 was shown to be stimulated
through a pathway other than one involving
TLR2.
Arthritis is a frequent complication of Lyme
borreliosis. Intermittent episodes of arthritis
develop in c. 60% of individuals infected with
B. burgdorferi, especially in North America [70,71].
In severe cases, chronic inflammatory Lyme arth-
ritis involves cartilage and bone erosion, leading
to permanent joint dysfunction [72,73]. Elevated
expression of functional TLR2 has been reported
in synovial fibroblasts of patients affected by
rheumatoid arthritis [74,75], indicating that rheu-
matoid arthritis synovial fibroblasts respond to
TLR2 ligands by up-regulation of various chem-
okines [17]. Our own studies have shown a
differential expression of chemokines by human
synovial cells exposed to different B. burgdorferi
isolates. Thus, it is possible that different strains
of B. burgdorferi can stimulate synovial cells
through TLRs either directly or indirectly. This
differential expression of chemokines, together
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with other inflammatory factors, might contribute
to the clinical variability in Lyme disease patients.
It can be hypothesised that spirochaetal products,
e.g., lipoproteins, flagellin or others, could be
present in the joint as potential ligands of TLRs.
GENERAL PROPERTIES OF TLR
SIGNALLING PATHWAYS
To a large extent, the specificities of the TLRs, and
the way they signal, have now been deciphered.
Four adaptor proteins, MyD88 (myeloid differen-
tiation factor 88), MAL ⁄TIRAP (MyD88-adaptor
like ⁄TIR associated protein), TRIF (Toll-receptor
associated activator of interferon) and TRAM
(Toll-receptor associated molecule), transduce sig-
nals from all of the TIR (Toll ⁄ interleukin-1 recep-
tor (IL-1R) homologous region) domains,
activating protein kinases and then the transcrip-
tion factors that cause inflammatory effects [76].
MyD88 was isolated originally as a primary
response gene in myeloid differentiation. It was
induced rapidly after stimulation of M1 myelo-
leukaemic cells by IL-6 [77]. Later, MyD88 was
found to be related structurally to the IL-1R family
and, in particular, to TLRs [78]. Knock-out studies
defined MyD88-dependent and MyD88-inde-
pendent pathways of TLR responses [79] (Fig. 2).
Binding of PAMP to a particular TLR leads to
the activation of TIR, and triggers a series of
events leading to increased expression of pro-
inflammatory genes. TLRs and the related inter-
leukin 1 receptors (IL-1Rs) share considerable
homology in their cytoplasmic regions, including
a conserved homophilic domain of c. 200 amino-
acids, known as the Toll-IL-1R domain. TLRs and
IL-1Rs also share a common adaptor molecule,
MyD88, which contains a Toll-IL-1R domain.
After binding of a ligand, MyD88 is recruited to
the TLR ⁄TIR receptor complex, which is then
joined by IL-1R-associated protein kinase-1
(IRAK-1), IRAK-4 and tumour necrosis factor
receptor-associated factor 6 (TRAF6). IRAK-1
and TRAF-6 then dissociate from this complex
and associate with another complex of transform-
ing growth factor b-activated kinase (TAK-1) and
TAK-1 binding proteins 1 and 2. TAK-1 is activa-
ted, which in turn activates the IjB kinase (IKK)
complex. IKK-mediated phosphorylation of IjB
leads to its ubiquitination and degradation, there-
by unmasking the nuclear localisation domain of
NF-jB [80]. After NF-jB translocation into the
nucleus, NF-jB can activate multiple pro-inflam-
matory genes, including TNF-a, IL-1 and IL-6
[80].
Evidence is accumulating to indicate that dif-
ferent TLRs activate different signalling pathways
and exert distinct biological effects. MyD88 is a
shared adaptor molecule in IL-1, IL-18 and TLR
signalling [81]. The importance of MyD88 as a
component of TLR signalling is highlighted by the
observations that MyD88-deficient mice have
increased susceptibility to infection with patho-
gens including Staphylococcus aureus [82], L. mono-
cytogenes [83], Toxoplasma gondii [84] and
Mycobacterium avium [85]. In addition, MyD88-
dependent responses have been found to be
essential in streptococcal cell-wall-induced joint
inflammation [86,87]. The MyD88-dependent
pathway is essential for activation of the NF-jB
and MAP kinases in response to all TLR ligands
other than TLR4. However, the fact that each TLR
ligand induces different patterns of gene expres-
sion in the same cell indicates that each TLR
signal harbours MyD88-independent pathways
(which may not activate either NF-jB or MAP
kinases), in addition to the MyD88-dependent
pathway [88].
Liu et al. [89] have demonstrated that MyD88
deficiency impairs pathogen clearance, but does
not alter inflammation in Borrelia-infected mice
[89]. Bolz et al. [87] observed that MyD88-defici-
ent mice had extremely high numbers of B.
burgdorferi in tissues when compared with wild-
type litter-mates, and larger numbers of spiro-
chaetes in tissues than did TLR2-deficient mice.
This suggests that, in addition to TLR2, other
pathways involving MyD88 play a significant role
in host defence to B. burgdorferi [87].
In addition, a MyD88-independent pathway
exists for stimulation by TLR4, and this leads to
two major biological effects provoked by LPS,
namely cytokine production and co-stimulatory
molecule up-regulation. This MyD88-independ-
ent pathway may be linked to virus infection as it
activates interferon regulatory factor-3 (IRF-3),
leading to induction of IFN-c and IFN-inducible
genes, as observed for a range of infections. It has
been reported that MyD88 plays a unique role in
host defence, but it does not seem to be relevant
for the development of arthritis in Lyme disease
[87].
Type-I interferons, acting through their own
receptors, activate the Janus kinases (JAK), which
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in turn phosphorylate signal transducer and
activator of transcription (STAT) proteins, leading
to the transcriptional activation of other genes,
including many that are required for effective
antiviral defence and genes encoding proteins
involved in the inflammatory response [90]. In the
case of TLR4, association with at least three
proteins occurs, namely MyD88, MyD88-adap-
tor-like associates (MaL, also known as Toll ⁄ IL-1R
domain-containing adaptor protein; TIRAP), and
the TIR domain containing adaptor-inducing IFN
(TRIF). This suggests that additional MyD88-like
adaptor molecules may associate with some TLRs
to mediate additional specific responses [91].
TIRAP ⁄MaL forms homo- or hetero-dimers with
MyD88, and associates with IRAK-2, thereby
leading to NF-jB activation [92,93]. An additional
molecule involved in TLR-mediated signalling
has now been identified as RICK ⁄Rip2 ⁄CAR-
DIAK [94,95].
ROLE OF CD14 IN BORRELIA -
INDUCED INFLAMMATION
Vertebrates and invertebrates initiate a series of
defence mechanisms following infection with
bacteria or other microorganisms. The best-char-
acterised example for innate recognition is the
innate inflammatory response to LPS. In the case
of LPS, the pattern recognition receptors are lipid-
binding protein (LBP) and CD14. It is known that
LPS binds first to LBP, a plasma lipid transfer
protein that moves LPS monomers from aggre-
gates or bacterial membranes to a binding site of
CD14. LBP binds to LPS via lipid A [96], and
thereby lowers the threshold stimulatory concen-
trations of LPS. However, B. burgdorferi lacks lipid
A [44]. CD14, a leucine-rich protein, is expressed
both in plasma (soluble CD14, sCD14) and as a
glycosylphosphatidylinositol (GPI)-anchored pro-
tein on leukocytes (membrane CD14, mCD14)
[97]. mCD14 lacks both trans-membrane and
cytoplasmic domains [98]. Therefore, mCD14 is
unable to transduce signals into the cytoplasm.
It has been demonstrated that TLR4 acts as an
additional signalling molecule in mammalian
cells for the CD14-mediated transcriptional
response to LPS. Acyl-modified lipoprotein of
B. burgdoferi is a potent activator of mono-
cytes ⁄macrophages, B-cells and endothelial cells.
The inflammatory signalling of B. burgdorferi
lipoproteins is mediated by CD14 [6] and TLR2
[99]. According to Sellati et al. [100], the CD14-
dependent signalling pathways used by LPS and
spirochaetal lipoproteins ⁄ lipopeptides differ in at
least two fundamental respects. In contrast to
LPS, activation by spirochaetal lipoproteins is not
facilitated by LBP or other serum components
[100]. The absence of involvement of LBP in cell
activation by lipoproteins and lipopeptides sug-
gests that these amphiphilic compounds either
interact with CD14 as aggregates, or that mono-
mers bind to CD14 unassisted by a serum inter-
mediary such as LBP [100]. This type of LPS
activation has also been reported in S. aureus.
Cell-wall extracts of S. aureus stimulate human
PBMCs in a CD14-dependent, but LBP-independ-
ent, pathway [101].
LBP has been shown to be expressed in he-
patocytes, alveolar epithelial cells and intestinal
cells. Thus, LBP is apparently present in com-
partments of the organism exposed to larger
quantities of microorganisms, and may play a
key role in early recognition of pathogens. LBP is
reported to enhance LPS responsiveness by trans-
ferring LPS monomers out of LPS aggregates to a
binding site of CD14 [102]. It has been demon-
strated that activation of monocytes and human
umbilical vein endothelial cells by spirochaetal
lipoproteins and lipopeptides is enhanced by
CD14, particularly at low doses [6,100]. The
dependence on CD14 was lost at higher concen-
trations of lipoproteins [6]. It seems apparent that
spirochaetal lipoproteins follow a CD14-inde-
pendent stimulatory pathway at higher concen-
trations. Elevated levels of soluble CD14 (sCD14)
exist in the synovial fluid of patients with B.
burgdorferi infection in their affected joints, com-
pared with normal levels in serum [103]. CD14 is
also involved in cellular responses to triacylated
and diacylated lipopeptides. Lipopeptides dis-
play a pattern of recognition via TLR2, in combi-
nation with TLR1 and ⁄ or TLR6, related to their
different degree of acylation. There are similari-
ties in the signalling pathways of LPS and
lipoproteins, which indicate that they converge
by stimulation of the nuclear translocation factor
NF-jB [104].
CONCLUSIONS
Lyme arthritis, the most common manifestation of
late Lyme disease, has been associated with the
presence of B. burgdorferi in the joint [105,106]. The
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abundantly expressed borrelial lipoproteins are
intricately involved in the pathology of Lyme
disease. Targeting TLRs, the lipoproteins possess
potent stimulatory properties for inflammatory
host cells, e.g., neutrophils, mononuclear cells,
endothelial cells, etc., that are present in affected
joints [99]. Thus, an understanding of the molecu-
lar basis of the signalling events elicited by
lipoproteins should lead to a greater understand-
ing of inflammation in Lyme arthritis.
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